“Using ISCAS adjudication services is too costly – it’s cheaper to look elsewhere.”
If you’ve heard this, it’s time to bust the myth.
- ISCAS: Independent, Not-for-Profit, Expert
ISCAS (Independent Sector Complaints Adjudication Service) is owned by the Centre for Effective Dispute Resolution (CEDR), a UK charity. As a not-for-profit organisation, ISCAS reinvests any surplus into improving adjudication services, ensuring value without compromising independence. It is also the only adjudicator solely focused on private healthcare complaints – making it the most experienced and sector-informed choice in the market. - Transparency and Evidence
The latest available ISCAS annual data (2024–25 figures) shows:
• Average adjudication cost: £1,590 (down from previous years)
• Average financial goodwill award: £843
• Complaint outcomes: 39% not upheld, 37% partially upheld, 24% upheld
This demonstrates fair, balanced decision-making, while keeping costs competitive. Independent adjudication isn’t just about numbers – it’s about trust, accountability, and reputational integrity. - The True Value Beyond Cost
Opting for independent adjudication with ISCAS offers benefits that can’t be measured in pounds alone:
• Patient trust: An impartial adjudicator reassures patients that complaints are handled fairly.
• Transparency: Clear, independent decisions reinforce confidence in your service.
• Reputational integrity: Demonstrating commitment to accountability enhances public perception and strengthens your brand.
• Sector insights: ISCAS provides intelligence and guidance to help providers improve care and reduce future complaints. - Myth-Busting in Practice
While some competitors may advertise lower flat fees, anecdotal evidence often ignores the value of expertise, independence, and sector-specific knowledge. ISCAS continues to prove that cost-effective adjudication and high-quality outcomes are not mutually exclusive.
In short: choosing ISCAS is not about spending more – it’s about investing wisely in fairness, trust, and compliance.
Conclusion:
Independent adjudication with ISCAS is an investment in patient confidence, organisational integrity, and sector leadership. The actual costs are moderate and trending downward, while the benefits are significant, both for patients and healthcare providers.
Don’t let myths guide your decision – choose ISCAS for reliable, independent adjudication.